Medical Technologies

Isomorphic Labs raises $5 billion to boost AI drug discovery research

Isomorphic Labs, specializing in AI-driven drug discovery, has successfully raised $5 billion in a Series C funding round to support the transition of its drug candidates to the clinical trial phase.

2026-11-17
2 min read
3 views
certi.news Editorial Team
Isomorphic Labs raises $5 billion to boost AI drug discovery research

A massive funding boost toward clinical trials

Isomorphic Labs, a spin-off from Alphabet's DeepMind, has announced the closing of a $5 billion Series C funding round. This funding comes at a critical time as the company seeks to move its drug candidates from the laboratory to the actual clinical trial phase.

The funding round was led by Greenoaks and Sequoia Capital, with participation from new investors such as Andreessen Horowitz, alongside continued support from existing investors including Alphabet's investment arms (GV and CapitalG), Thrive Capital, MGX, Temasek, and the UK's sovereign AI fund.

The technology behind the innovation

Isomorphic Labs relies on an advanced drug design engine that uses generative AI models to explore vast chemical spaces. This technology is based on the legacy of the famous AlphaFold model, which revolutionized the prediction of three-dimensional protein structures. The company announced that its programs have achieved positive results in preclinical stages in the fields of oncology and immunology.

The company has strengthened its market position through strategic partnerships with pharmaceutical industry giants, such as Eli Lilly, Novartis, and Johnson & Johnson.

Why does this news matter?

This funding represents a turning point for the company, as it follows a previous funding round of $2.1 billion last May, reflecting significant investor confidence in integrating artificial intelligence into drug research processes. The new funds will be allocated to developing the company's drug design engine and expanding into new types of medical treatments.

This step also comes during a transitional phase for the company, as its founder and CEO Demis Hassabis is dedicating himself entirely to drug discovery, having previously served as the head of DeepMind. He is a Nobel laureate in Chemistry in recognition of his work on the AlphaFold system.

Although the company has not disclosed its new financial valuation, media reports indicated that the company was targeting a valuation of up to $50 billion, placing it at the forefront of startups attempting to reshape the future of medicine through advanced computing.

News source
TechCrunch AI
Open original source ↗
c
Author

certi.news Editorial Team

In the same category

You may also like

View all news